You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201311 - 201320 of 207727 results
  1. COMPUTERIZED CROSS-CULTURAL COMPETENCY ASSESSMENT PROGRAM FOR HEALTH ORGANIZATION

    SBC: NESHER TECHNOLOGIES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Arthritis is a heterogeneous disease of the 'whole joint', whereby different combinations of proteolytic enzymes are active in different patient subpopulations leading to progressive joint degeneration. Upfront identification and stratification is critical for appropriate intervention with specific inhibitors, several of which are being evaluated in ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Hollow Fiber Catheter for Drug Delivery into the Prostate

    SBC: PROGENITEC INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Chronic non-healing wounds continue to pose great challenges to clinicians. It is estimated that there are 1.1-1.8 million new chronic wound patients each year and approximately 8 million Americans suffering from chronic wounds. To make the situation worse, chronic wounds often predispose the patients to infection. The problem is compounded by the lack of effe ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer

    SBC: Max Biopharma, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoporosis affects 10 million Americans and another 34 million are osteopenic and at risk for developing osteoporosis. Bone fractures, the most important complication of the disease, cause substantial morbidity and mortality in the aging population as well as significant socio-economic cost. Since the 1960's, bisphosphonate drug therapy has produced cli ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

    SBC: Vidasym, Inc            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoporosis is a major public health threat. National Osteoporosis Foundation estimated that the US national direct expenditures for osteoporotic hip fractures were at 17 billion in 2005 and it would increase to 25billion in 2025. Current treatments for osteoporosis include several anti-resorptive (or anti-catabolic) and some anabolic agents. VDRMs such as ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Restoring arm and hand motor function with non-invasive spinal stimulation.

    SBC: Q-Track Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): Q-Track seeks to develop a Sports Medicine Assessment Tool (SMAT) to provide comprehensive kinematic and physiological data to trainers, coaching staff, and athletes. In addition to the safety benefit of monitoring thevital condition of players in real time, our goal is to develop a fatigue management system. The purpose of this proposal is to integrate kinema ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Modular Ultrasonic Beacon System (MUBS) for Ultrasound-guided Interventional Surg

    SBC: Nymirum, Inc.            Topic: NIAMS

    DESCRIPTION: Myotonic dystrophy 1 (DM1) is the leading form of adult muscular dystrophy resulting in progressive neuromuscular effects. The disease affects 1 in 6000 people. Nymirum is interested in identifying a small molecule that can be used to slow oreliminate the progression of DM1. The cause of DM1 is the expansion of a CUG RNA sequence within the DMPK gene. This repeat RNA is toxic to no ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Broadly protective (universal) virus-like particle (VLP) based influenza vaccine

    SBC: ALGOMEDIX, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): A safe and effective therapeutic for treatment of osteoarthritis (OA) represents a major unmet medical need. OA is the leading cause of disability in the US and pain is a predominant clinical feature. However, chronicuse of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with potentially life-threatening gastrointestinal bleeding and calculations ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Design of an Interactive Incentive Spirometer for Enhanced Respiratory Care

    SBC: AMBRYX BIOTECHNOLOGY, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Cancer and rheumatoid arthritis (RA) share remarkably similar pathogenic pathways. For example, in both cancer and RA, angiogenesis, chronic inflammation and reactive oxygen species create a negative feedback loop thataccelerates disease progression. In the synovium of RA patients, fibroblast-like synoviocytes (RA- FLS) has features of tumor-like transformation ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Administrative supplement to 5R44DA025375-03: Prescription drug abuse prevention

    SBC: WELLGEN, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Type 2 Diabetes (T2D) is an inflammatory disease affecting 26 million people in the US (11%) and is predicted to affect more than 30% of adults in the US by 2050. The economic cost of T2D is over 200 billion a year. People with T2D suffer from hyperglycemia due to low insulin production, poor transport of insulin, or cellular resistance to insulin which can l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Automated Sample Preparation for Next Generation Sequencing Cancer Diagnostics

    SBC: ADVANCED LIQUID LOGIC            Topic: NCI

    DESCRIPTION (provided by applicant): As more diverse genetic links are established with cancer, the utility of one-gene-one-test diagnostics is diminished. In addition, biopsies are mixed populations of tumor and normal tissue, requiring deconvolution oftumor and non-tumor genoptypes to accurately understand disease etiology and inform treatment decisions. The next generation of cancer diagnostic ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government